CagriSema is a two-peptide fixed combination the amylin analogue cagrilintide co-administered with the GLP-1 receptor agonist semaglutide whereas tirzepatide is a single engineered molecule that activates two receptors (GIP and GLP-1) at once
The Subcutaneous Dosing Reality Now heres where things gets interesting The commonly cited research-use only dosages of 100250 mcg subcutaneously once daily for sleep optimization are based on case reports and observational studies, not on controlled trials that demonstrated the efficacy of DSIP Does this necessarily invalidate the subcutaneous use of DSIP
However, its important to speak with your doctor before starting any new supplement or medication especially if youre pregnant, breastfeeding, or taking other prescriptions
Those with respiratory issues or mold sensitivities are more at risk
Subscribe to our newsletter for supplement education, healthy lifestyle tips, and practical wellness guidance
However, their therapeutic outcomes are limited because of drug resistance due to the intracellular inactivation effect (Johnstone et al., 2016)